What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?
7 brokerages have issued twelve-month price objectives for Ocular Therapeutix's stock. Their predictions range from $5.84 to $35.00. On average, they anticipate Ocular Therapeutix's share price to reach $22.31 in the next year.
When will Ocular Therapeutix announce their earnings?
Ocular Therapeutix is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)
According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (10/12/2016)
Who owns Ocular Therapeutix stock?
Ocular Therapeutix's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (10.53%), SV Life Sciences Advisers LLC (6.45%), State Street Corp (0.96%), Renaissance Technologies LLC (0.58%), Opaleye Management Inc. (0.38%) and A.R.T. Advisors LLC (0.21%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Charles M Warden, James Fortune and Svlsf Iv, Llc.
Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?
Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and SV Life Sciences Advisers LLC.
Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?
Ocular Therapeutix's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Opaleye Management Inc., A.R.T. Advisors LLC, State Street Corp, Dynamic Technology Lab Private Ltd, Pacad Investment Ltd., Trexquant Investment LP and Ellington Management Group LLC.
How do I buy Ocular Therapeutix stock?
Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ocular Therapeutix stock cost?
One share of Ocular Therapeutix stock can currently be purchased for approximately $8.15.